Disruption of differentiation in human cancer: AML shows the way
The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Abstract
Although much is understood about the ways in which transcription factors regulate various differentiation systems, and one of the hallmarks of many human cancers is a lack of cellular differentiation, relatively few reports have linked these two processes. Recent studies of acute myeloid leukaemia (AML), however, have indicated how disruption of transcription-factor function can disrupt normal cellular differentiation and lead to cancer. This model involves lineage-specific transcription factors, which are involved in normal haematopoietic differentiation. These factors are often targeted in AML--either by direct mutation or by interference from translocation proteins. Uncovering these underlying pathways will improve the diagnosis and treatment of AML, and provide a working model for other types of human cancer, including solid tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Autoregulation may be a common feature of several transcriptional regulators to augment the relatively irreversible nature of differentiation processes in the hematopoietic system (60,61).”
From Potential Autoregulation of Transcription Factor PU.1 by an Upstream Regulatory Element (2005) · cites this paper as [60]
Citations
Cites
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864 · cited 1×
“What is the role of lineage-specific transcription factors on stem cells, and how does this relate to AML? Although most of the blast cells from patients with AML clearly show a lineage- and stage-specific differentiation block, several studies support the idea that it is a disease that also involves the stem-cell com…”
BackgroundBennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Purification and Characterization of Mouse Hematopoietic Stem Cells
Spangrude, G. J., Heimfeld, S., & Weissman, I. L. (1988) · Science · doi:10.1126/science.2898810 · Cited by 2,824
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617
In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Schwarze, S. R., Ho, A., Vocero-Akbani, A., & Dowdy, S. F. (1999) · Science · doi:10.1126/science.285.5433.1569 · Cited by 2,416
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 1×
“This could be applied either in treating bone marrow ex vivo with differentiation agents, followed by bone-marrow transplantation for re-introduction into the patient, or by local therapies, such as instillation into the lung by bronchoscop”
MethodOkuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856 · cited 1×
“Whereas AML1 falls into the category of transcription factors that are involved in the development of haematopoietic cells from haemangioblasts (SCL is another), and disruption of AML1 results in loss of all definitive haematopoiesi”
Background
Research works printed but not linked: 2
- Zhang, P. et al. C/EBPα deficiency blocks granulocytic differentiation at the common myeloid progenitor stage in both adult and fetal liver myelopoiesis. Blood 98, 792a (2001).
- Duprez, E. A., Koch, H. & Tenen, D. G. C/EBPβ is an important target of PML–RARA during ATRA induced differentiation of APL cells. Blood 98, 833a (2001).
Cited by
Items 301–400 of 620
Emerging Role for MicroRNAs in Acute Promyelocytic Leukemia
Nervi, C., Fazi, F., Rosa, A., Fatica, A., & Bozzoni, I. (2007) · Springer eBooks · doi:10.1007/978-3-540-34594-7_5 · Cited by 26
“Indeed, C/EBPα knockout mice lack neutrophils and eosinophils but retain monocytes (Zhang et al. 1997; Tenen 2003).”
BackgroundInfluentialOrfali, N. M., O’Donovan, T. R., Cahill, M. R., Benjamin, D., Nanus, D. M., McKenna, S. L., Gudas, L. J., & Mongan, N. P. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13367 · Cited by 25
“transcription factor involved in early myeloid differentiation but downregulated during the terminal phase of the process (Figure 1C).(35) The mRNA levels of the ITGAM gene encoding CD11b, a frequently used surface marker of myeloid differentiation, were greatly increased (Figure 1B).”
BackgroundmiR‐204 is dysregulated in metastatic prostate cancer in vitro
Todorova, K. O., Metodiev, M. V., Metodieva, G., Zasheva, D., Mincheff, M. S., & Hayrabedyan, S. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22263 · Cited by 26
Mitochondria in human pluripotent stem cell apoptosis
TeSlaa, T. A., Setoguchi, K., & Teitell, M. A. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.01.027 · Cited by 27
Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia
Oing, C., Jost, E., Dahl, E., Wilop, S., Brümmendorf, T. H., & Galm, O. (2011) · Clinical Epigenetics · doi:10.1007/s13148-011-0043-5 · Cited by 25
“Important genetic findings in AML comprise chromosomal translocations involving different transcription factors and activating point mutations in multiple signal transduction pathways (Tenen 2003).”
BackgroundWu, X., Gao, H., Ke, W., Giese, R. W., & Zhu, Z. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45556 · Cited by 26
Cofré, J., Menezes, J. R. L., Pizzatti, L., & Abdelhay, E. S. F. W. (2012) · Cancer Cell International · doi:10.1186/1475-2867-12-28 · Cited by 27
“1 is a hematopoietic lineage- specific ETS (Erythroblast Transformation Specific) family member [57] that is absolutely required for normal hematopoiesis [58].”
BackgroundClinical Translation of Genotyping and Haplotyping Data
Vizirianakis, I. S. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746100-00001 · Cited by 25
Bench, A. J., Erber, W. N., & Scott, M. A. (2005) · Clinical & Laboratory Haematology · doi:10.1111/j.1365-2257.2005.00701.x · Cited by 28
Xiang, F., Zhu, Z., Zhang, M., Wang, J., Chen, Z., Li, X., Zhang, T., Gu, Q., Wu, R., & Kang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627856 · Cited by 24
“Therefore, reversing methylation of tumor suppressor genes may be a promising strategy for cancer prevention and treatment (16, 17).”
BackgroundFan, H., Wang, F., Zeng, A. G. X., Murison, A., Tomczak, K. J., Hao, D., Jelloul, F. Z., Wang, B., Barrodia, P., Liang, S., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05120-6 · Cited by 25
Aberrant DNA methylation of the transcription factor C/EBPα in acute myelogenous leukemia
Jost, E., do Ó, N., Wilop, S., Herman, J. G., Osieka, R., & Galm, O. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.07.027 · Cited by 24
“Transcription factor lterations, including core binding factor (CBF) complex bnormalities, have been implicated in the disruption of ell differentiation in AML [1].”
BackgroundWinteringham, L. N., Endersby, R., Kobelke, S., McCulloch, R. K., Williams, J. H., Stillitano, J. P., Cornwall, S. M. J., Ingley, E., & Klinken, S. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605401200 · Cited by 28
Vizirianakis, I. S., Chatzopoulou, M., Bonovolias, I. D., Nicolaou, I., Demopoulos, V. J., & Tsiftsoglou, A. S. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100189a · Cited by 28
MicroRNA-Regulated Pathways in Hematological Malignancies: How to Avoid Cells Playing Out of Tune
Fatica, A., & Fazi, F. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141020930 · Cited by 25
“A tumour can be regarded as tissue in which cells “lose their identity”, become malignant and start to grow in an uncontrolled or inappropriate manner instead of developing into their determined cell type [5].”
BackgroundDNA methylation at enhancer regions Novel avenues for epigenetic biomarker development
Helgason, C. D. (2016) · Frontiers in bioscience · doi:10.2741/4399 · Cited by 25
Janik, S., Nowak, U. M., Łaszkiewicz, A., Satyr, A., Majkowski, M., Marchwicka, A., Śnieżewski, Ł., Berkowska, K., Gabryś, M. S., Cebrat, M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061323 · Cited by 24
Zhao, X., Liu, H., Wang, L., Yang, L., & Liu, X. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.010 · Cited by 25
Wang, Y., Wang, H., Lv, X., Liu, C., Qi, L., Song, X., & Yu, A. (2013) · Macromolecular Bioscience · doi:10.1002/mabi.201300295 · Cited by 24
PAP: a comprehensive workbench for mammalian transcriptional regulatory sequence analysis
Chang, L.-W., Fontaine, B. R., Stormo, G. D., & Nagarajan, R. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm308 · Cited by 24
Mori, M. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1346 · Cited by 25
“Tumours can originate from stem or progenitor cells and epigenetic alterations are involved in cellular differentiation as in BCR/ABL translocation-positive haematopoietic stem cells in chronic myelogenous leukaemia and Lgr5-positive stem cells in CRC (1-3).”
BackgroundDisruption of C/EBPα Function in Acute Myeloid Leukemia
Fröhling, S., & Döhner, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048241 · Cited by 24
Metz, A., Schanda, J., Grez, M., Wichmann, C. W., & Gohlke, H. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400332e · Cited by 25
Karjalainen, E., & Repasky, G. A. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.09.005 · Cited by 28
Liu, N., Song, J., Xie, Y., Wang, X.-L., Rong, B., Man, N., Zhang, M.-M., Zhang, Q., Gao, F.-F., Du, M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809327116 · Cited by 25
“In leukemia, genes encoding transcription factors are frequently involved in chromosomal translocation and mutation (4), and the resulting fusion/mutant proteins often acquire new interactions with other transcription factors and cofactors, thereby altering transcriptional networks and blocking hematopoietic different…”
BackgroundEstrada‐Capetillo, L., Aragoneses‐Fenoll, L., Domínguez‐Soto, Á., Fuentelsaz‐Romero, S., Nieto, C., Simón‐Fuentes, M., Alonso, B., Portolés, P., Corbí, A. L., Rojo, J. M., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202048806 · Cited by 22
Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance
Rudich, A., Garzon, R., & Dorrance, A. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012271 · Cited by 25
“Aside from the treatment challenges presented by LSCs, impaired differentiation is an established obstacle in both AML and BP CML [75,76].”
BackgroundIriyama, N., Yuan, B., YOSHINO, Y., Hatta, Y., Horikoshi, A., Aizawa, S., Takei, M., Takeuchi, J., Takagi, N., & Toyoda, H. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2236 · Cited by 22
“Although a number of studies have been conducted to explore the molecular mechanism underlying the effects of ATRA on these transcription factors associated with differentiation induction (16,18,19,22), the effects of VPA alone or in combination with ATRA on human APL cell line harboring PML-RARα remain largely unclea…”
BackgroundPerrotti, D., Silvestri, G., Stramucci, L., Yu, J. E., & Trotta, R. (2016) · Current Drug Targets · doi:10.2174/1389450117666160615074120 · Cited by 24
B-cell identity as a metabolic barrier against malignant transformation
Chan, L. N., & Müschen, M. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.06.004 · Cited by 25
“While myeloid leukemia cells frequently acquire genetic lesions in myeloid transcription fa ctors [29], pre-B ALL clones often carry genetic lesions that r esults in reduced activity or inactivation of B-lym phoid transcription factors [18,30,31].”
Transcriptional and epigenetic regulation of the GM-CSF promoter by RUNX1
Taberlay, P. C., James, S. R., Qadi, A. A., West, A. C., Ray, S., Bert, A. G., Cockerill, P. N., & Holloway, A. F. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.03.029 · Cited by 26
Cancer stem cells: lessons from leukaemia
Bonnet, D. A. (2005) · Cell Proliferation · doi:10.1111/j.1365-2184.2005.00353.x · Cited by 23
“This concept is supported by a correlation between the genes required for normal haematopoietic development and those perturbed in leukaemia (Tenen 2003), and by the recent demonstration that Bmi-1 plays a key role in self-renewal determination in both normal and leukaemic murine stem cells…”
MethodLong Non-coding RNAs as Functional and Structural Chromatin Modulators in Acute Myeloid Leukemia
Wurm, A. A., & Pina, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00899 · Cited by 24
Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML
Cammenga, J. (2005) · Leukemia · doi:10.1038/sj.leu.2403894 · Cited by 26
PU.1: An ETS Family Transcription Factor That Regulates Leukemogenesis Besides Normal Hematopoiesis
Gupta, P., Gangenahalli, G. U., Verma, Y. K., Kishore, V., Gulati, S., Sharma, R. K., Chandra, R., & Saluja, D. (2006) · Stem Cells and Development · doi:10.1089/scd.2006.15.609 · Cited by 21
“Besides their role in transcriptional regulation, they are equally important in leukemogenesis, because their aberrant expression or function abrogates normal cell differentiation and supports uncontrolled proliferation (2).”
PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.
Ueno, S., Tatetsu, H., Hata, H., Iino, T., Niiro, H., Akashi, K., Tenen, D. G., Mitsuya, H., & Okuno, Y. (2009) · Oncogene · doi:10.1038/onc.2009.263 · Cited by 20
“These data indicate that inappropriate regulation of the PU.1 gene, including failure of downregulation or upregulation in proper differentiation stages, leads to hematological malignancies in different hematological lineages (Tenen, 2003).”
BackgroundSelf-citationRamos, F. J. D. C., Muniz, M. T. C., Cavalcante‐Silva, V., de Araújo, M., Leite, E. P., Freitas, E. M., Zanrosso, C. W., Hatagima, A., de Mello, M. P., Yunes, J. A., et al. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600800132 · Cited by 20
“The AML subtypes are often characterized by genetic alterations such as scattered mutations and chromosomal alterations, including translocations, inversions, and deletions [1].”
BackgroundMLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF
Wang, X., Ros, U., Agrawal, D., Keller, E. C., Slotta‐Huspenina, J., Dill, V., Shen, B., Shi, R., Herold, T., Belka, C., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00811-1 · Cited by 20
Therapeutic targeting of leukemia stem cells in acute myeloid leukemia
Barbosa, K., & Deshpande, A. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1204895 · Cited by 23
Behan, K. J., Fair, J., Singh, S., Bogwitz, M. R., Perry, T., Grubor, V. D., Cunningham, F., Nichols, C. D., Cheung, T. L., Batterham, P., et al. (2005) · Development Genes and Evolution · doi:10.1007/s00427-005-0490-0 · Cited by 20
“RUNX1 is the alpha subunit of the core-binding factor and has been widely studied for its role in blood development and leukemogenesis (Tenen 2003).”
BackgroundKapoor, I., Kanaujiya, J. K., Kumar, Y., Thota, J. R., Bhatt, M. L. B., Chattopadhyay, N., Sanyal, S., & Trivedi, A. K. (2015) · Oncotarget · doi:10.18632/oncotarget.6156 · Cited by 21
“Myeloid leukemia represents a heterogenous malignancy of hematopoietic stem cell disorders characterized by differentiation blockade and overproliferation of clonal myeloid cells, resulting in accumulation of non-functional myeloid cells, termed myeloblasts [1-4].”
BackgroundChen, S., Yu, J., Lv, X., & Zhang, L. (2017) · Cell Biochemistry and Function · doi:10.1002/cbf.3293 · Cited by 20
“It is characterized by the accumulation of granulocyte or monocyte precursors in the bone marrow and peripheral blood.(1) Acute myeloid leukaemia has the lowest survival rate of all leukaemias.”
BackgroundYang, J., Qiao, M., Li, Y., Hu, G., Song, C., Xue, L., Bai, H., Yang, J., & Yang, X. (2018) · Mediators of Inflammation · doi:10.1155/2018/9031452 · Cited by 20
Low serum miR‐223 expression predicts poor outcome in patients with acute myeloid leukemia
Yu, G., Yin, Z., He, H., Zheng, Z., Chai, Y., Xuan, L., Lin, R., Wang, Q., Li, J., & Xu, D. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23096 · Cited by 20
Preleukemic and leukemic evolution at the stem cell level
Stauber, J., Greally, J. M., & Steidl, U. G. (2020) · Blood · doi:10.1182/blood.2019004397 · Cited by 22
Role of microRNAs in myeloid differentiation
Fatica, A., Rosa, A., Ballarino, M., Marchis, M. L. D., Rasmussen, K. D., & Bozzoni, I. (2008) · Biochemical Society Transactions · doi:10.1042/bst0361201 · Cited by 22
Valentin, J. (2005) · Annals of the ICRP · doi:10.1016/j.icrp.2005.11.005 · Cited by 20
Rubino, V., Hüppi, M., Höpner, S., Tortola, L., Schnüriger, N., Legenne, H., Taylor, L., Voggensperger, S., Keller, I., Bruggmann, R., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101826 · Cited by 19
“48 All-trans retinoic acid is the first approved drug that induces the differentiation of blasts in a specific subtype of AML.”
Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies
Kobayashi, M., Chen, S., Gao, R., Bai, Y., Zhang, Z., & Liu, Y. (2014) · Cell Cycle · doi:10.4161/15384101.2014.954448 · Cited by 19
“It usually occurs around age 60 with no identifiable cause and carries a very poor prognosis, with most patients living less than 18 months.(72,73) Unfortunately, little progress has been made in treating AML over the past 4 decades.”
BackgroundDecoding early myelopoiesis from dynamics of core endogenous network
Su, H., Wang, G., Yuan, R., Wang, J., Tang, Y., Ao, P., & Zhu, X. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9059-y · Cited by 23
Temporal autoregulation during human PU.1 locus SubTAD formation
Schuetzmann, D., Walter, C., van Riel, B., Kruse, S., König, T., Erdmann, T., Tönges, A., Bindels, E. M., Weilemann, A., Gebhard, C., et al. (2018) · Blood · doi:10.1182/blood-2018-02-834721 · Cited by 20
Ward, C., Cauchy, P., García, P., Frampton, J., Esteban, M. A., & Volpe, G. (2020) · Scientific Reports · doi:10.1038/s41598-020-60480-x · Cited by 19
E3 ligase SCFSKP2 ubiquitinates and degrades tumor suppressor C/EBPα in acute myeloid leukemia
Thacker, G., Mishra, M., Sharma, A., Singh, A., Sanyal, S., & Trivedi, A. K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118041 · Cited by 20
Thakral, D., Gupta, R., & Khan, A. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10349-5 · Cited by 21
Sritana, N., & Auewarakul, C. U. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.09.004 · Cited by 19
“The initiation and transformation of the leukemic clone in AML has been proposed to occur as the consequence of cooperation between at least two groups of gene mutations (Gilliland, 2002); (Tenen, 2003).”
BackgroundManzotti, G., Parenti, S., Ferrari‐Amorotti, G., Soliera, A. R., Cattelani, S., Montanari, M., Cavalli, D., Ertel, A., Grande, A., & Calabretta, B. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1033591 · Cited by 25
“In particular, lineage-specific transcription factors are mutated or functionally inactivated in AML, suggesting a pathogenic link with the aberrant differentiation of AML cells.(4) One such gene, the transcription factor C/EBPa, is required for granulocytic differentiation of normal myeloid progenitors and is frequen…”
BackgroundRiccioni, R., Rossini, A., Calabrò, L., Diverio, D., Pasquini, L., Lo‐Coco, F., Peschle, C., & Testa, U. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/104281090310001646031 · Cited by 19
“the capacity to block the differentiation process at a specific stage (reviewed in [4]).”
BackgroundRetinoids and TRAIL: Two Cooperating Actors to Fight Against Cancer
Altucci, L., & Gronemeyer, H. (2004) · Vitamins and hormones · doi:10.1016/s0083-6729(04)67017-8 · Cited by 23
LINC01128 resisted acute myeloid leukemia through regulating miR-4260/NR3C2
Li, H., Tian, X., Wang, P., Hu, J., Qin, R., Xu, R., Liu, K., Hao, J., & Tian, N. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1740054 · Cited by 18
“The pathogenesis of AML could result from genetic or epigenetic alterations.(3,4) However, the detailed mechanism underlying AML remains incompletely understood.”
BackgroundA novel vitamin D gene therapy for acute myeloid leukemia
Xu, Y., Payne, K. J., Pham, L. H. G., Eunwoo, P., Xiao, J., Chi, D., Lyu, J., Campion, R. D. N., Wasnik, S., Jeong, I. S. D., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100869 · Cited by 18
“Acute myeloid leukemia (AML) is a bone marrow (BM) malignancy in which immature hematopoietic myeloid precursors have lost their ability to differentiate and are locked in a highly proliferative state [1,2].”
BackgroundTan, J. Y., Yang, X., Jiang, X., Zhou, J., Li, Z., Lee, P. L., Li, B., Robson, P., & Yu, Q. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.283 · Cited by 18
“Loss of differentiation is an important component in the pathogenesis of many cancers.(13) It has been previously reported that many differentiation genes are transcriptionally repressed by Polycomb repressive complex 2 (PRC2) through”
BackgroundYoshida, H., Imamura, T., Fujiki, A., Hirashima, Y., Miyachi, M., Inukai, T., & Hosoi, H. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.01.009 · Cited by 18
“Recent tudies have also demonstrated that C/EBP acts as a tumour supressor in a number of malignancies, supporting the view that he disruption of normal cellular differentiation and its uncoupling rom cell cycle arrest are key components in the development of ancer [2,3].”
BackgroundSoliera, A. R., Lidonnici, M. R., Ferrari‐Amorotti, G., di Prisco, M., Zhang, Y., Martinez, R. V. P., Donato, N. J., & Calabretta, B. (2008) · Blood · doi:10.1182/blood-2007-09-114975 · Cited by 18
Thacker, G., Mishra, M., Sharma, A., Singh, A., Sanyal, S., & Trivedi, A. K. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29516 · Cited by 18
Ubiquitylation in normal and malignant hematopoiesis: novel therapeutic targets
Marteijn, J. A. F., Jansen, J. H., & van der Reijden, B. A. (2006) · Leukemia · doi:10.1038/sj.leu.2404319 · Cited by 21
“Several proteins involved in blood cell development are known to be regulated by the UPS”
BackgroundKhanna‐Gupta, A., Abayasekara, N., Levine, M. S., Sun, H., Virgilio, M., Nia, N., Halene, S., Sportoletti, P., Jeong, J., Pandolfi, P. P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.373274 · Cited by 18
Mans, S., Banz, Y., Mueller, B. U., & Pabst, T. (2012) · Blood · doi:10.1182/blood-2012-02-412759 · Cited by 17
“Lineage specific transcription factors such as CCAAT/enhancer binding protein-alpha (CEBPA) are crucial for normal neutrophil maturation, and they are obvious targets for disruption in AML [1-3].”
BackgroundChandran, P., Kavalakatt, A., Malarvizhi, G. L., Vasanthakumari, D. R. V. N., Retnakumari, A. P., Sidharthan, N., Pavithran, K., Nair, S. V., & Koyakutty, M. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.09.008 · Cited by 19
PU.1 and CEBPA expression in acute myeloid leukemia
D’Alò, F., Ruscio, A. D., Guidi, F., Fabiani, E., Greco, M., Rumi, C., Hohaus, S., Voso, M. T., & Leone, G. G. M. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.01.007 · Cited by 17
Koch, C., Samareh, B., Morishima, T., Mir, P., Kanz, L., Zeidler, C., Skokowa, J., & Welte, K. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2894-5 · Cited by 18
Transcribing malignancy: transcription-associated genomic instability in cancer
Boulianne, B., & Feldhahn, N. (2017) · Oncogene · doi:10.1038/onc.2017.402 · Cited by 18
Chan, S., Liang, P., & Guh, J. (2018) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-018-1484-6 · Cited by 17
Pabst, T., Stillner, E., Neuberg, D. S., Nimer, S. D., Willman, C. L., List, A. F., Melo, J. V., Tenen, D. G., & Mueller, B. U. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06057.x · Cited by 17
“The transcription factor CEBPA (for CCAAT/enhancerbinding protein alpha) is a general inhibitor of cell proliferation and a tumour suppressor (Tenen, 2003).”
BackgroundSelf-citationTranscriptionally imprinted glycomic signatures of acute myeloid leukemia
Blöchl, C., Wang, D., Mayboroda, O. A., Lageveen‐Kammeijer, G. S. M., & Wuhrer, M. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00981-0 · Cited by 17
“The compiled set of hematopoietic TFs plays a key role in the pathobiology of AML and regulates its aberrantly low differentiation status [45, 60].”
BackgroundCore binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis
Guo, M., Chan, H. M. T., Zhou, Q., An, Ö., Li, Y., Song, Y., Tan, Z. H., Ng, H. E. V., Peramangalam, P. S., Tan, Z. Q., et al. (2023) · Blood · doi:10.1182/blood.2022015830 · Cited by 24
Self-citationSelenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells
Misra, S., Selvam, A. K., Wallenberg, M., Ambati, A., Matolcsy, A., Magalhaes, I., Lauter, G., & Björnstedt, M. (2016) · Oncotarget · doi:10.18632/oncotarget.12531 · Cited by 16
“1, an important transcription factor for myeloid and lymphoid cells differentiation [6, 7], and thereby compete and interfere with the hematopoietic cell differentiation [4].”
BackgroundZhao, F., Sun, L., Yang, N., Zheng, W., Shen, P., Huang, Y., & Lü, Y. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112213 · Cited by 18
Qu, M., Duan, Y., Zhao, M., Wang, Z., Zhao, M., Zhao, Y., Wang, H., Ke, Y., Liu, Y., Liu, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659720 · Cited by 16
Cancer stem cells: AMLs show the way
Bonnet, D. A. (2005) · Biochemical Society Transactions · doi:10.1042/bst0331531 · Cited by 20
Imai, N., Miwa, H., Shikami, M., Suganuma, K., Gotoh, M., Hiramatsu, A., Wakabayashi, M., Watarai, M., Hanamura, I., Imamura, A., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.03.006 · Cited by 16
TCEA1 regulates the proliferative potential of mouse myeloid cells
Yang, T., Cui, H., Wen, M., Zuber, J. A., Kogan, S. C., & Wei, G. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.07.020 · Cited by 16
“This opposing process is critical for normal development and keeping homeostasis in myeloid cells, while it is frequently disrupted during tumorigenesis [36].”
Core-binding factor leukemia hijacks the T-cell–prone PU.1 antisense promoter
van der Kouwe, E., Heller, G., Czibere, A. G., Pulikkan, J. A., Agreiter, C., Castilla, L. H., Delwel, R., Ruscio, A. D., Ebralidze, A. K., Forte, M., et al. (2021) · Blood · doi:10.1182/blood.2020008971 · Cited by 18
Self-citationLung cancer: Developmental networks gone awry?
Dong, J., Kislinger, T., Jurišica, I., & Wigle, D. A. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.4.7522 · Cited by 16
Oancea, C., Rüster, B., Brill, B., Roos, J., Heinßmann, M., Bug, G., Mian, A. A., Guillen, N., Kornblau, S. M., Henschler, R., et al. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.39 · Cited by 16
“AMLs are frequently associated with specific chromosomal translocations and their related aberrant fusion proteins (AAFPs)[4] such as PML/RARα, DEK/NUP214 or RUNX1/RUNX1T1.”
BackgroundMultiple ways of C/EBPα inhibition in myeloid leukaemia
Trivedi, A. K., Pal, P., Behre, G., & Singh, S. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.04.022 · Cited by 16
Loss of C/EBPα and Favorable Prognosis of Acute Myeloid Leukemias: A Biological Paradox
Perrotti, D., Marcucci, G., & Caligiuri, M. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.965 · Cited by 18
“[2].”
BackgroundStorti, F. (2008) · Cited by 16
Understanding stem cell differentiation through self-organization theory
Qu, K., & Ortoleva, P. (2007) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2007.10.019 · Cited by 18
“…contexts in the pure and applied life sciences, e.g. tissue transplantation, repair of tissue damages, embryonic development and cancer (Kirschstein et al., 2001; Yu et al., 2006; Jordan et al., 2006; Tannishtha et al., 2001; Passegue et al., 2003; Tenen, 2003; Broxmeyer et al., 2006; Atala, 2006).”
BackgroundA Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation
Radomska, H. S., Jernigan, F. E., Nakayama, S., Jorge, S. E., Sun, L., Tenen, D. G., & Kobayashi, S. S. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115592220 · Cited by 16
“Consistent with its importance in normal myeloid differentiation, expression and/or function of C/EBPα are perturbed in various types of myeloid leukemias by different mechanisms (transcriptional silencing, translational inhibition, posttranslational modification, decrease in DNA binding, or point mutations resulting…”
Self-citationMarchwicka, A., Corcoran, A., Berkowska, K., & Marcinkowska, E. (2016) · Cell & Bioscience · doi:10.1186/s13578-016-0075-9 · Cited by 15
“AML is characterized by the accumulation of primitive hematopoietic blast cells, which lose their ability of normal differentiation [10].”
BackgroundLearning about the Importance of Mutation Prevention from Curable Cancers and Benign Tumors
Wang, G., Chen, L., Yu, B., Zellmer, L., Xu, N., & Liao, D. J. (2016) · Journal of Cancer · doi:10.7150/jca.13832 · Cited by 15
“dedifferentiation [21], such as via mutation in the PIK3CA gene [22], or by preventing differentiation of undifferentiated embryonic cells or stem cells, i.”
BackgroundMishra, S., 刘, J. 军. L., Chai, L., & Tenen, D. G. (2022) · PubMed · doi:10.1097/moh.0000000000000692 · Cited by 13
“Acute myeloid leukemia (AML) is characterized by an expansion of the abnormal myeloid progenitor cells in the bone marrow and blood resulting from differentiation block [1].”
Self-citationPullarkat, S. T., Pullarkat, V. A., Lagoo, A. S., Brynes, R. K., Weiss, L. M., Bedell, V., Chen, W., Huang, Q., Gaal, K. K., Weisenburger, D. D., et al. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.08.010 · Cited by 15
Niebuhr, B., Iwanski, G. B., Schwieger, M., Roscher, S., Stocking, C., & Cammenga, J. (2008) · Leukemia · doi:10.1038/leu.2008.332 · Cited by 17
“1 The discovery of these mutations confirmed a long-standing hypothesis that the disruption of genes regulating differentiation is a critical step in leukemogenesis”
BackgroundCaspase‐1 promotes monocyte–macrophage differentiation by repressing PPAR γ
Niu, Z., Tang, J., Zhang, W., Chen, Y., Huang, Y., Chen, B., Li, J., & Shen, P. (2017) · FEBS Journal · doi:10.1111/febs.13998 · Cited by 16
CDK2-instigates C/EBPα degradation through SKP2 in Acute myeloid leukemia
Thacker, G., Mishra, M., Sharma, A., Singh, A., Sanyal, S., & Trivedi, A. K. (2021) · Medical Oncology · doi:10.1007/s12032-021-01523-9 · Cited by 15
“Loss of CEBPα expression and function promoting leukemogenesis have been attributed to multiple mechanisms ranging from CEBPα promoter hypermethylation, regulation at promoter levels, antagonistic protein–protein interactions and more importantly post translational modifications (PTM) [5, 8, 11].”
BackgroundRichards, S. J., & Jack, A. (2003) · Clinical & Laboratory Haematology · doi:10.1046/j.0141-9854.2003.00559.x · Cited by 15
“The development of new technologies together with fundamental advances in understanding the biology of disease has meant that present-day leukaemia diagnosis is now vastly different from routine practise 10–15 years ago (Shaffer, Rosenwald & Staudt, 2002; Tenen, 2003).”
BackgroundYun, H., Zoller, J., Zhou, F., Rohde, C., Liu, Y., Blank, M. F., Göllner, S., & Müller‐Tidow, C. (2024) · Leukemia · doi:10.1038/s41375-024-02322-7 · Cited by 15
“Acutemyeloid leukemia (AML) is a hematological malignancy characterized by impaired hematopoiesis that affects the myeloid lineage [12].”
BackgroundmicroRNAs : role in leukemia and their computational perspective
Omer, A., Singh, P. C., Yadav, N. K., & Singh, R. K. (2014) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1256 · Cited by 14
Qian, M., Jin, W. Y., Zhu, X., Jia, X., Yang, X., Du, Y., Wang, K., & Zhang, J. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-25 · Cited by 14
“1, one of these master TFs, is exclusively expressed in hematopoietic cells and has been identified as a crucial transcription factor in normal hematopoiesis and in generation of myeloid leukemia through disruption of its function [2].”
Background
Metadata
- Authors
- Tenen, D. G.
- Affiliations
- Harvard University (US)
- Corresponding author
- Tenen, Daniel G.
- ORCID
- Tenen, Daniel G.
- Venue
- Nature Reviews Cancer
- Published
- 2003-02
- Volume
- 3
- Issue
- 2
- Pages
- 89-101
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2050249118
- Cited by
- 612
- References
- 128
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 16 · 2023: 15 · 2022: 6 · 2021: 23 · 2020: 20 · 2019: 16 · 2018: 17 · 2017: 22 · 2016: 20 · 2015: 18 · 2014: 25 · 2013: 33 · 2012: 27
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- acute myeloid leukemia, cell differentiation, transcription factors, lineage-specific transcription factors, hematopoietic differentiation, transcription factor mutations, solid tumors
- MeSH terms
- Cell Differentiation, Humans, Mutation, Neoplasms, Transcription Factors, Leukemia, Myeloid, Acute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.